Сергей Вялов - О чем молчит печень. Как уловить сигналы самого крупного внутреннего органа, который предпочитает оставаться в тени

3. Yeh M.M., Brunt E.M. Pathological features of fatty liver disease. Gastroenterology . 2014 Oct. 147 (4): 754–764.

4. Chalasani N., Younossi Z., Lavine J.E. et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology . 2018 Jan. 67 (1): 328–357.

5. Kim D., Choi S.Y., Park E.H. et al. Nonalcoholic fatty liver disease is associated with coronary artery calcification. Hepatology . 2012 Aug. 56 (2): 605–613.

6. Garcia-Galiano D., Sanchez-Garrido M.A., Espejo I. et al. IL-6 and IGF-1 are independent prognostic factors of liver steatosis and non-alcoholic steatohepatitis in morbidly obese patients. Obes Surg . 2007 Apr. 17 (4): 493–503.

7. Promrat K., Kleiner D.E., Niemeier H.M. et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology . 2010 Jan. 51 (1): 121–129.

8. Yamamoto M., Iwasa M., Iwata K. et al. Restriction of dietary calories, fat and iron improves non-alcoholic fatty liver disease. J Gastroenterol Hepatol . 2007 Apr. 22 (4): 498–503.

9. Kistler K.D., Brunt E.M., Clark J.M., Diehl A.M., Sallis J.F., Schwimmer J.B. Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease. Am J Gastroenterol . 2011 Mar. 106 (3): 460–468; quiz 469.

1. Casanova J., Bataller R. Alcoholic hepatitis: prognosis and treatment. Gastroenterol Hepatol . 2014 Apr. 37 (4): 262–268.

2. [Guideline] O’Shea R.S., Dasarathy S., McCullough A.J. Alcoholic liver disease. Hepatology . 2010 Jan. 51 (1): 307–328.

3. [Guideline] Singal A.K., Bataller R., Ahn J., Kamath P.S., Shah V.H. ACG clinical guideline: alcoholic liver disease. Am J Gastroenterol . 2018 Feb. 113 (2): 175–194.

4. Mihas A.A., Tavassoli M. Laboratory markers of ethanol intake and abuse: a critical appraisal. Am J Med Sci . 1992 Jun. 303 (6): 415–428.

5. Lucey M.R. Management of alcoholic liver disease. Clin Liver Dis . 2009 May. 13 (2): 267–275.

6. Rahimi E, Pan JJ. Prognostic models for alcoholic hepatitis. Biomark Res . 2015 Jul 21. 3: 20.

7. Llopis M., Cassard A.M., Wrzosek L, et al. Intestinal microbiota contributes to individual susceptibility to alcoholic liver disease. Gut . 2016 May. 65 (5): 830–839.

8. Mitchell M.C., Friedman L.S., McClain C.J. Medical management of severe alcoholic hepatitis: expert review from the Clinical Practice Updates Committee of the AGA Institute. Clin Gastroenterol Hepatol . 2017 Jan. 15 (1): 5–12.

1. [Guideline] Lee W.M., Larson A.M., Stravitz R.T. AASLD position paper: the management of acute liver failure: update 2011. Hepatology.

2. Khandelwal N., James L.P., Sanders C., Larson A.M., Lee W.M. Acute Liver Failure Study Group. Unrecognized acetaminophen toxicity as a cause of indeterminate acute liver failure. Hepatology . 2011 Feb. 53 (2):567-76.

3. Alempijevic T., Zec S., Milosavljevic T. Drug-induced liver injury: do we know everything? World J Hepatol . 2017 Apr 8. 9 (10):491–502.

4. Marrone G., Vaccaro F.G., Biolato M. et al. Drug-induced liver injury 2017: the diagnosis is not easy but always to keep in mind. Eur Rev Med Pharmacol Sci . 2017 Mar. 21 (1 Suppl):122-34.

5. Lo Re V. 3rd, Haynes K., Forde K.A. et al. Risk of acute liver failure in patients with drug-inducedliver injury: evaluation of Hy’s law and a new prognostic model. Clin Gastroenterol Hepatol . 2015 Dec. 13 (13): 2360–2368.

6. [Guideline] Chalasani N.P. Hayashi P.H., Bonkovsky H.L., Navarro V.J., Lee W.M., Fontana R.J. et al. ACG clinical guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol . 2014 Jul. 109 (7): 950–966; quiz 967.

7. Stine J.G., Lewis J.H. Current and future directions in the treatment and prevention of drug-induced liver injury: a systematic review. Expert Rev Gastroenterol Hepatol . 2016. 10 (4): 517–536.

1. Aggarwal R., Goel A. Hepatitis A: epidemiology in resource-poor countries. Curr Opin Infect Dis . 2015 Oct. 28(5): 488–496.

2. Worns M.A., Teufel A., Kanzler S. et al. Incidence of HAV and HBV infections and vaccination rates in patients with autoimmune liver diseases. Am J Gastroenterol . 2008 Jan. 103 (1): 138–146.

3. Kanda T., Nakamoto S., Wu S. et al. Direct-acting antivirals and host-targeting agents against the hepatitis A virus. J Clin Transl Hepatol . 2015 Sep 28. 3(3): 205–210.

4. Linder K.A., Malani P.N. Hepatitis A. JAMA . 2017 Dec 19. 318 (23): 2393.

5. Kamar N., Bendall R., Legrand-Abravanel F. et al. Hepatitis E. Lancet . 2012 Jun 30. 379 (9835): 2477–2488.

6. Hoofnagle J.H., Nelson K.E., Purcell R.H. Hepatitis E. N Engl J Med . 2012 Sep 27. 367 (13): 1237–1244.

7. Mushahwar I.K. Hepatitis E virus: molecular virology, clinical features, diagnosis, transmission, epidemiology, and prevention. J Med Virol . 2008 Apr. 80 (4): 646–658.

8. Nelson K.E., Heaney C.D., Labrique A.B., Kmush B.L., Krain L.J. Hepatitis E: prevention and treatment. Curr Opin Infect Dis . 2016 Oct. 29 (5): 478–485.

9. Wedemeyer H., Pischke S., Manns M.P. Pathogenesis and treatment of hepatitis E virus infection. Gastroenterology . 2012 May. 142 (6): 1388–1397.e1.

10. Debing Y., Moradpour D., Neyts J., Gouttenoire J. Update on hepatitis E virology: Implications for clinical practice. J Hepatol . 2016 Jul. 65(1): 200–212.

11. [Guideline] European Association for the Study of the Liver. EASL clinical practice guidelines on hepatitis E virus infection. J Hepatol . 2018 Jun. 68 (6): 1256–1271.

12. [Guideline] American Association for the Study of Liver Diseases, Infectious Diseases Society of America. HCV guidance: Recommendations for testing, managing, and treating hepatitis C. Updated: May 24, 2018.

13. [Guideline] World Health Organization. Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection. Geneva, Switzerland: World Health Organization. July 2018.

14. Sterling R.K., Bralow S. Extrahepatic manifestations of hepatitis C virus. Curr Gastroenterol Rep . 2006 Feb. 8 (1): 53–59.

15. Kamili S., Drobeniuc J., Araujo A.C., Hayden T.M. Laboratory diagnostics for hepatitis C virus infection. Clin Infect Dis . 2012 Jul. 55 suppl 1: S43–438.

16. Yang D.H, Ho L.J, Lai J.H. Useful biomarkers for assessment of hepatitis C virus infection-associated autoimmune disorders. World J Gastroenterol . 2014 Mar 21. 20 (11): 2962–2970.

17. Omar H., E.l. Akel W., Elbaz T. et al. Generic daclatasvir plus sofosbuvir, with or without ribavirin, in treatment of chronic hepatitis C: real-world results from 18 378 patients in Egypt. Aliment Pharmacol Ther . 2018 Feb. 47 (3): 421–431.

18. Shahid I., AlMalki W.H., Hassan S., Hafeez M.H. Real-world challenges for hepatitis C virus medications: a critical overview. Crit Rev Microbiol . 2018 Mar. 44 (2): 143–160.

19. Te H.S., Jensen D.M. Epidemiology of hepatitis B and C viruses: a global overview. Clin Liver Dis . 2010 Feb. 14 (1): 1–21, vii.

20. Kuo A., Gish R. Chronic hepatitis B infection. Clin Liver Dis . 2012 May. 16 (2): 347–369.

21. Lau J.Y., Wright T.L. Molecular virology and pathogenesis of hepatitis B. Lancet . 1993 Nov 27. 342 (8883): 1335–1340.